67Cu-SARTATE (67Cu-SAR-[Tyr3]-Octreotate) is a therapeutic radiolabeled somatostatin analogue of 64Cu-SARTATE and the first Copper-67 labeled drug that entered clinical trials.
67Cu-SARTATE is targeting first meningioma but in reality, is a competitor to existing somatostatin analogue labeled tracers developed in the NET indication. 67Cu-SARTATE entered phase I/II trials in meningioma patients Australia in May 2019 . The study (5 patients) was completed in September 2019. Another clinical Phase I/II trial in pediatric patients with high risk neuroblastoma was initiated in July 2019, but the recruitment started only in July 2020 with an expected completion in September 2022.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.